| anti-β2GPI | anti-β2-glycoprotein I |
| aCL | Anticardiolipin antibodies |
| Anti-PS/PT | anti-phosphatidylserine/prothrombin antibodies |
| APS | Antiphospholipid syndrome |
| aPL | Antiphospholipid antibodies |
| EC | Endothelial cells |
| EPCR | endothelial protein C receptor |
| HCQ | hydroxychloroquine |
| ICH | intracerebral haemorrhage |
| LA | lupus anticoagulant |
| LDA | low dose aspirin |
| LMWH | Low molecular weight heparin (LMWH |
| NO | Nitric oxide |
| eNOS | Nitric oxide synthase |
| PAI-I | Plasminogen activator inhibitor I |
| RA | Rheumatoid arthritis |
| SLE | systemic lupus erythematosus |
| TM | Thrombomodulin |
| TF | Tissue factor |
| TFPI | Tissue factor pathway inhibitor |
| tPA | Tissue-plasminogen activator |
| TLR4 | Toll like receptor 4 |
| UFH | unfractionated heparin |
| USPSTF | US Preventive Services Task Force |
| VKA | vitamin K antagonists |
| VWF | von Willebrand factor |